Last reviewed · How we verify

NCT03980756

A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole

Completed Phase 1 Last updated 13 January 2021
What this trial tests

Phase 1 trial testing AD-206 20mg in Gastritis in 88 participants. Completed in 18 June 2020.

Timeline
5 June 2019
Primary endpoint
27 April 2020
18 June 2020

Quick facts

Lead sponsorAddpharma Inc.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment88
Start date5 June 2019
Primary completion27 April 2020
Estimated completion18 June 2020
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Addpharma Inc. — full company profile →

Who can join

Adults 19 to 50, male only, with Gastritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-206 to Esomeprazole in healthy male volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.
    Bae S, Kwon J, Lee SB, Jang IJ, et al · · 2021 · cited 8× · PMID 34992346 · DOI 10.2147/dddt.s341271

Verify or expand the search:

Other recruiting trials for Gastritis

Currently open trials in the same condition.

Other Addpharma Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03980756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing